Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | MFN2 | O95140 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700011 | 1.00 | EPHX2 (0.62) | EPHX2EPHX1MFN2HPGDHTT | |
| SCHEMBL4180735 | 0.94 | EPHX2 (0.69) | EPHX2EPHX1HDAC2HDAC8HDAC6 | |
| SCHEMBL30645033 | 0.90 | EPHX1 (0.77) | EPHX2EPHX1MFN2HDAC2 | |
| SCHEMBL22289572 | 0.88 | EPHX1 (0.75) | EPHX2EPHX1MFN2HDAC2 | |
| SCHEMBL22289565 | 0.88 | EPHX1 (0.75) | EPHX2EPHX1MFN2HDAC2 | |
| SCHEMBL22289564 | 0.88 | EPHX1 (0.75) | EPHX2EPHX1MFN2HDAC2 | |
| SCHEMBL28554753 | 0.87 | EPHX2 (0.80) | EPHX2EPHX1HPGD | |
| SCHEMBL17705940 | 0.87 | EPHX2 (0.75) | EPHX2EPHX1HPGDHDAC2HDAC8 | |
| SCHEMBL22289846 | 0.86 | EPHX2 (0.54) | EPHX2EPHX1MFN2HPGDHTT | |
| SCHEMBL22289848 | 0.86 | EPHX2 (0.54) | EPHX2EPHX1MFN2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| EP-1575586-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | Pfizer Japan Inc. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | KAWAI MAKOTO (JP) | 2004-08-05 | — | — | US | disclosed |
| WO-2004054579-A1 | 2-PYRIDYL AND 2-PYRIMIDYL CYCLOALKYLENE AMIDE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152715-A1 | Cycloalkylene amide compounds as NR2B receptor antagonists | GRIN1, GRIN3A, GRIN2A | EPHX2 2150/4885EPHX1 2232/4885MFN2 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.